Persistent hypofibrinolysis in severe COVID-19 associated with elevated fibrinolysis inhibitors activity, 2024, Okazaki et al.

Persistent hypofibrinolysis in severe COVID-19 associated with elevated fibrinolysis inhibitors activity
Okazaki, Erica; Barion, Bárbara Gomes; da Rocha, Tania Rubia Flores; Di Giacomo, Giovanna; Ho, Yeh-Li; Rothschild, Cynthia; Fatobene, Giancarlo; de Carvalho Moraes, Bruna del Guerra; Stefanello, Bianca; Villaça, Paula Ribeiro; Rocha, Vanderson Geraldo; Orsi, Fernanda Andrade

Hypercoagulability and reduced fibrinolysis are well-established complications associated with COVID-19. However, the timelines for the onset and resolution of these complications remain unclear. The aim of this study was to evaluate, in a cohort of COVID-19 patients, changes in coagulation and fibrinolytic activity through ROTEM assay at different time points during the initial 30 days following the onset of symptoms in both mild and severe cases.

Blood samples were collected at five intervals after symptoms onset: 6–10 days, 11–15 days, 16–20 days, 21–25 days, and 26–30 days. In addition, fibrinogen, plasminogen, PAI-1, and alpha 2-antiplasmin activities were determined. Out of 85 participants, 71% had mild COVID-19. Twenty uninfected individuals were evaluated as controls. ROTEM parameters showed a hypercoagulable state among mild COVID-19 patients beginning in the second week of symptoms onset, with a trend towards reversal after the third week of symptoms.

In severe COVID-19 cases, hypercoagulability was observed since the first few days of symptoms, with a tendency towards reversal after the fourth week of symptoms onset. A hypofibrinolytic state was identified in severe COVID-19 patients from early stages and persisted even after 30 days of symptoms. Elevated activity of PAI-1 and alpha 2-antiplasmin was also detected in severe COVID-19 patients. In conclusion, both mild and severe cases of COVID-19 exhibited transient hypercoagulability, reverted by the end of the first month. However, severe COVID-19 cases sustain hypofibrinolysis throughout the course of the disease, which is associated with elevated activity of fibrinolysis inhibitors.

Persistent hypofibrinolysis could contribute to long COVID-19 manifestations.

Link | PDF (Journal of Thrombosis and Thrombolysis)